Utility and Usability of ActivSight™ Laser Speckle Imaging in Visualization of Tissue Perfusion and Blood Flow During Esophageal Surgery in Humans
Esophagus Cancer, Esophageal Cancer, Esophageal Neoplasms
About this trial
This is an interventional diagnostic trial for Esophagus Cancer focused on measuring laparoscopic, robot assisted surgery, gastrointestinal anastomoses, esophagectomy, esophageal surgery, thoracic surgery, alimentary surgery, perfusion, indocyanine green (ICG), laser speckle contrast imaging (LSCI), cancer, minimally invasive surgery (MIS)
Eligibility Criteria
INCLUSION CRITERIA
All patients age > 18 years old undergoing laparoscopic esophageal resection and reconstruction surgery; spoken command and literacy in the native language spoken at each participating center; ability to understand and follow study procedures; and having provided signed consent.
Diagnosis:
- All patients with a clinical suspicion and diagnosis of benign or malignant, small or large bowel lesions requiring surgical resection.
- Typical imaging as per standard workup findings including US, CT and/or MRI. Plain radiographs and contrast imaging may be obtained by referring physicians and are helpful for confirming the clinical diagnosis.
Location of pathology or resected segment:
* Target lesions can be located in any fore-, mid- or hindgut segments requiring reconstruction and anastomoses.
Prior therapy:
* Patients with prior surgery are eligible for enrollment.
Laboratory:
- Hemoglobin > 9 g/dL
- Platelet count ≥75,000/µL (may receive transfusions)
- Normal PT, PTT and INR < 1.5 x ULN (including patients on prophylactic anticoagulation)
- Renal function: Age-adjusted normal serum creatinine derived from Schwartz formula for estimating GFR by the CDC OR a creatinine clearance ≥60 mL/min/1.73 m2 for safe
- Adequate pulmonary function: Defined as no dyspnea at rest, and a pulse oximetry >94% on room air if there is clinical indication for determination.
EXCLUSION CRITERIA
- There is no exclusion criteria for ActivSightTM for esophageal surgery.
- Patients assigned to FDA cleared ICG-based visualization are contraindicated for any chronic renal dysfunction, potential drug interaction, history of allergy to ICG or anaphylaxis, known allergy to iodides, breast-feeding or being of reproductive age with pregnancy possible and not ruled out, and pregnancy.
- Patients currently in any investigational agents.
Sites / Locations
- University of Pittsburgh Medical Center - Dept of Cardiothoracic SurgeryRecruiting
- West Penn Hospital / Allegheny Health Network
Arms of the Study
Arm 1
Experimental
ActivSight Group
Patients undergoing esophagectomy with ActivSight (n=70)